Novartis has launched its TOBI Podhaler tobramycin dry powder inhaler in the UK. The DPI, for the treatment of P. aeruginosa infections in cystic fibrosis patients. The CF Trust responded to the launch on its website, noting “This is the first ever antibiotic pod haler and is a development the CF Trust welcomes.”
Read a brief article.
published on
Featured event:
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 28-October 30: Deutches Aerosol Therapie Symposium (DATS), Marburg, Germany
October 28, 2026: Webinar: From Guidance to Practice: Navigating Revised FDA PSGs for Inhaled Products, online
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland
April 27-30: RDD Europe 2027, Antibes, France
